0000000000741438

AUTHOR

Marina Aloi

showing 5 related works from this author

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of…

2019

Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florenc…

medicine.medical_specialtyPopulationadalimumab efficacy03 medical and health sciences0302 clinical medicineadalimumab efficacy; adalimumab safety; infliximab failure; pediatric crohn’s diseaseRheumatologyInternal medicinemedicineAdalimumabinfliximab failureImmunology and AllergyTargets and Therapy [Biologics]Pharmacology (medical)Adverse effecteducationPediatric gastroenterologyOriginal ResearchCrohn's diseaseeducation.field_of_studybusiness.industryAdalimumab efficacy; Adalimumab safety; Infliximab failure; Pediatric Crohn’s disease; Immunology and Allergy; Rheumatology; Oncology; Gastroenterology; Pharmacology (medical)Gastroenterologyadalimumab safetyHepatologymedicine.diseaseInfliximabOncology030220 oncology & carcinogenesisCohortpediatric Crohn’s disease030211 gastroenterology & hepatologybusinessmedicine.drugBiologics : Targets & Therapy
researchProduct

Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

2022

Objective: The aim was to assess the awareness and real-life use of biosimilars in inflammatory bowel disease (IBD) among the members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Methods: An anonymous web survey involving all SIGENP IBD units which can prescribe biosimilars was conducted between July 1st and December 1st, 2020. The questionnaire included 18 questions addressing the most relevant aspects of biosimilars in pediatric IBD, i.e., advantages, disadvantages, costs, traceability, general knowledge, and real-life use. A descriptive analysis of responses was performed. Results: Responses came from 26 pediatric IBD units in Italy, with repre…

Inflammatory Bowel Diseasesbiosimilars; inflammatory bowel disease; childrendigestive system diseasesChild; Chronic Disease; Humans; Surveys and Questionnaires; Biosimilar Pharmaceuticals; Inflammatory Bowel DiseasesSurveys and QuestionnairesPediatrics Perinatology and Child HealthChronic DiseaseSurveys and QuestionnaireHumansPharmacology (medical)ChildBiosimilar PharmaceuticalsHumanBiosimilar Pharmaceutical
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

Epidemiological trends of pediatric IBD in Italy: A 10-year analysis of the Italian society of pediatric gastroenterology, hepatology and nutrition r…

2022

Introduction: The present study aimed at evaluating Italian epidemiological trends of pediatric inflammatory bowel diseases (IBD) over the period 2009–2018. Materials and methods: Data from 1969 patients enrolled in the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition Registry, by 49 pediatric IBD centers throughout the country, were analyzed, comparing three different time intervals (2009–2012, 2013–2015, 2016–2018). Results: The number of new IBD diagnoses ranged from 175 to 219 per year, evenly distributed over the examined period of time. From 2009 to 2018, the minimal incidence ranged from 1.59 to 2.04 /105 inhabitants aged < 18 years, with an overall slight p…

RegistrieDelayed DiagnosisHepatologyDelayed DiagnosiGastroenterologyPediatric IBDEpidemiological trendInflammatory Bowel DiseasesSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseItalyEpidemiological trendsHumansColitis UlcerativeRegistriesChildEpidemiological trends; Italy; Pediatric IBDHuman
researchProduct

P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey…

2021

Abstract Background Vaccine hesitancy, the delay in acceptance or refusal of vaccination despite its availability, represents a threat to the diffusion and lethality of infectious diseases. COVID-19 vaccination has been recommended by national and international organizations in patients with Inflammatory Bowel Diseases (IBD). The aim of the study was to evaluate COVID-19 vaccine willingness and hesitancy in a population of Italian patients with IBD, and their determinants. Methods In February 2021 an online questionnaire focused on COVID-19 vaccine was proposed to a representative sample of Italian IBD patients. Socio-demographic characteristics, IBD features, lifestyle, perception of COVID…

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryGastroenterologyInflammatory Bowel DiseasesGeneral MedicineClinical: Therapy and Observationmedicine.diseaseInflammatory bowel diseasePoster presentationsVaccinationVaccination RefusalFamily medicineMedicineIn patientAdverse effectbusinessAcademicSubjects/MED00260Journal of Crohn's & Colitis
researchProduct